Inactive Instrument

Perrigo Company Stock Nasdaq

Equities

US7142901039

Pharmaceuticals

End-of-day quote Nasdaq
- USD - Intraday chart for Perrigo Company
Sales 2024 * 4.62B Sales 2025 * 4.83B Capitalization 3.75B
Net income 2024 * -74M Net income 2025 * 103M EV / Sales 2024 * 1.51 x
Net Debt 2024 * 3.21B Net Debt 2025 * 3.01B EV / Sales 2025 * 1.4 x
P/E ratio 2024 *
-19 x
P/E ratio 2025 *
172 x
Employees -
Yield 2024 *
4.01%
Yield 2025 *
4.27%
Free-Float 99.66%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 55 23-06-29
Director of Finance/CFO 49 22-05-15
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Chairman 55 20-12-14
Director/Board Member 68 17-02-05
Director/Board Member 67 17-02-05
More insiders
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
More about the company